Show simple item record

dc.contributor.authorKorin, Netanel
dc.contributor.authorGounis, Matthew J.
dc.contributor.authorWakhloo, Ajay K.
dc.contributor.authorIngber, Donald E.
dc.date2022-08-11T08:10:46.000
dc.date.accessioned2022-08-23T17:19:10Z
dc.date.available2022-08-23T17:19:10Z
dc.date.issued2015-01-01
dc.date.submitted2015-03-11
dc.identifier.citationJAMA Neurol. 2015 Jan;72(1):119-22. doi: 10.1001/jamaneurol.2014.2886. <a href="http://dx.doi.org/10.1001/jamaneurol.2014.2886">Link to article on publisher's site</a>
dc.identifier.issn2168-6149 (Linking)
dc.identifier.doi10.1001/jamaneurol.2014.2886
dc.identifier.pmid25365638
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48009
dc.description.abstractObstruction of normal blood flow, which occurs in a variety of diseases, including thromboembolism in stroke and atherosclerosis, is a leading cause of death and long-term adult disability in the Western world. This review focuses on a novel nanotherapeutic drug-delivery platform that is mechanically activated within blood vessels by high-fluid shear stresses to selectively target drugs to sites of vascular obstruction. In vitro and in vivo studies have shown that this approach can be used to efficiently lyse clots using a significantly lower amount of thrombolytic drug than is required when administered in a soluble formulation. This nanotherapeutic strategy can potentially improve both the efficacy and safety of thrombolytic drugs, particularly in patients who are at high risk for brain hemorrhage, and thus provide a new approach for the treatment of many life-threatening and debilitating vascular disorders.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=25365638&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1001/jamaneurol.2014.2886
dc.subjectCardiovascular Diseases
dc.subjectNanomedicine
dc.subjectNervous System Diseases
dc.subjectRadiology
dc.subjectTherapeutics
dc.titleTargeted drug delivery to flow-obstructed blood vessels using mechanically activated nanotherapeutics
dc.typeJournal Article
dc.source.journaltitleJAMA neurology
dc.source.volume72
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiology_pubs/117
dc.identifier.contextkey6817959
html.description.abstract<p>Obstruction of normal blood flow, which occurs in a variety of diseases, including thromboembolism in stroke and atherosclerosis, is a leading cause of death and long-term adult disability in the Western world. This review focuses on a novel nanotherapeutic drug-delivery platform that is mechanically activated within blood vessels by high-fluid shear stresses to selectively target drugs to sites of vascular obstruction. In vitro and in vivo studies have shown that this approach can be used to efficiently lyse clots using a significantly lower amount of thrombolytic drug than is required when administered in a soluble formulation. This nanotherapeutic strategy can potentially improve both the efficacy and safety of thrombolytic drugs, particularly in patients who are at high risk for brain hemorrhage, and thus provide a new approach for the treatment of many life-threatening and debilitating vascular disorders.</p>
dc.identifier.submissionpathradiology_pubs/117
dc.contributor.departmentNew England Center for Stroke Research
dc.contributor.departmentDepartment of Radiology
dc.source.pages119-22


This item appears in the following Collection(s)

Show simple item record